A Phase 3 interventional study of Febuxostat and Allopurinol in Cardiovascular Disease, sponsored by Takeda. Completed at 203 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-06-14.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).
The drug tested in this study was called Febuxostat (TMX-67). Febuxostat compared with allopurinol was evaluated for the cardiovascular (CV) safety in people with gout and significant CV comorbidities.
The study enrolled 6198 patients. Participants with a diagnosis of gout were enrolled in a 1:1 ratio to receive either:
Participants received febuxostat 40 mg or 80 mg for the study depending on their serum uric acid levels were either \<6.0 mg/dL or ≥6.0 mg/dL during specified visits. Allopurinol 200 mg to 400 mg (for moderate renal impairment),or 300 mg to 600 mg (for normal and mild renal impairment), increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL was received.
This multi-center trial was conducted in Canada, Mexico and United States. The overall time to participate in this study was approximately 7 years (84 months). Participants made multiple visits to the clinic and were also contacted through the telephone.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.
This study's enrollment of 6,198 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has a history of major CV or cerebrovascular disease including at least one of the following:
The participant has a history or presence of gout defined as having one or more of the American Rheumatism Association criteria for the diagnosis of gout:
History of at least 6 of the following clinical, laboratory, and X-ray phenomena:
The participants must have either:
Exclusion Criteria:
Participants who meet any of the following criteria will not qualify for entry into this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
Drug: Febuxostat
Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance \[eCLcr\] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was \<6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but \<60 mL/min).
Drug: Allopurinol
Febuxostat tablets
Also known as: Uloric, TMX-67
Allopurinol tablets
Also known as: Zyloprim, Allohexal, Allosig, Milurit, Alloril, Progout, Zyloric, Puricos, Zyrik 300, Aluron
Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Primary MACE Composite (Final Analysis)
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event
APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Cardiovascular (CV) Death
Events were adjudicated by an independent cardiovascular endpoints committee as CV death.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Non-fatal Myocardial Infarction (MI)
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Non-fatal Stroke
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.
Time frame: Up to last dose of study drug (approximately 83 months)
Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization
Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.
Time frame: Up to last dose of study drug (approximately 83 months)
Participants took part in the study at 320 investigative sites in Canada, Mexico and United States from 23 April 2010 to 18 July 2017.
| Milestone | Febuxostat | Allopurinol |
|---|---|---|
| Started | 3101 | 3097 |
| Completed | 1704 | 1706 |
| Not completed | 1397 | 1391 |
| Withdrew: Adverse event | 191 | 172 |
| Withdrew: Major protocol deviation | 52 | 46 |
| Withdrew: Lost to follow-up | 226 | 223 |
| Withdrew: Voluntary withdrawal | 595 | 587 |
| Withdrew: Reason not specified | 333 | 363 |
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis) | 8.0 | 8.0 |
APTC events were defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event | 9.6 | 8.8 |
Events were adjudicated by an independent cardiovascular endpoints committee as CV death.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Cardiovascular (CV) Death | 4.3 | 3.2 |
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal MI.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Non-fatal Myocardial Infarction (MI) | 3.6 | 3.8 |
Events were adjudicated by an independent cardiovascular endpoints committee as non-fatal stroke.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Non-fatal Stroke | 2.3 | 2.3 |
Events were adjudicated by an independent cardiovascular endpoints committee as unstable angina with urgent coronary revascularization.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization | 1.6 | 1.8 |
Major adverse cardiovascular events (MACE) were defined as a composite of cardiovascular (CV) death, non-fatal myocardial infarction (MI), nonfatal stroke and unstable angina with urgent coronary revascularization; these events were adjudicated by an independent cardiovascular endpoints committee.
| percentage of participants | Febuxostat | Allopurinol |
|---|---|---|
| Percentage of Participants With Primary MACE Composite (Final Analysis) | 10.8 | 10.4 |
Collected over First dose of study drug to 30 days after last dose of study drug (Approximately 84 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat | 243/3,098 (7.8%) | 1,046/3,098 (33.8%) | 1,450/3,098 (46.8%) |
| Allopurinol | 199/3,092 (6.4%) | 995/3,092 (32.2%) | 1,467/3,092 (47.4%) |
| Event | Febuxostat | Allopurinol |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 139/3098 | 132/3092 |
| Cardiac failure congestiveCardiac disorders | 124/3098 | 109/3092 |
| PneumoniaInfections and infestations | 67/3098 | 88/3092 |
| Angina pectorisCardiac disorders | 74/3098 | 59/3092 |
| Acute myocardial infarctionCardiac disorders | 63/3098 | 68/3092 |
| Atrial fibrillationCardiac disorders | 65/3098 | 64/3092 |
| Coronary artery diseaseCardiac disorders | 51/3098 | 58/3092 |
| Myocardial infarctionCardiac disorders | 41/3098 | 51/3092 |
| Cerebrovascular accidentNervous system disorders | 45/3098 | 44/3092 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 34/3098 | 43/3092 |
| Event | Febuxostat | Allopurinol |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 258/3098 | 311/3092 |
| DiarrhoeaGastrointestinal disorders | 299/3098 | 284/3092 |
| Upper respiratory tract infectionInfections and infestations | 242/3098 | 267/3092 |
| HypertensionVascular disorders | 209/3098 | 261/3092 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 222/3098 | 218/3092 |
| Back painMusculoskeletal and connective tissue disorders | 216/3098 | 187/3092 |
| BronchitisInfections and infestations | 214/3098 | 212/3092 |
| Oedema peripheralGeneral disorders | 168/3098 | 183/3092 |
| Urinary tract infectionInfections and infestations | 146/3098 | 180/3092 |
| Blood creatine phosphokinase increasedInvestigations | 148/3098 | 161/3092 |
Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.
| Age, Continuous(years) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.58 | 65.0 ± 8.49 | 64.8 ± 8.53 |
| Age, Customized(Participants) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| <65 years | 1584 | 1506 | 3090 |
| 65 to <75 years | 1094 | 1135 | 2229 |
| ≥75 years | 420 | 451 | 871 |
| Sex: Female, Male(Participants) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Female | 494 | 500 | 994 |
| Male | 2604 | 2592 | 5196 |
| Race/Ethnicity, Customized(Participants) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| American Indian or Alaska Native | 262 | 234 | 496 |
| Asian | 92 | 96 | 188 |
| Black or African American | 552 | 593 | 1145 |
| Native Hawaiian or Other Pacific Islander | 13 | 14 | 27 |
| White | 2160 | 2140 | 4300 |
| Other | 19 | 15 | 34 |
| Race/Ethnicity, Customized(Participants) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Hispanic or Latino | 539 | 521 | 1060 |
| Not Hispanic or Latino | 2559 | 2571 | 5130 |
| Region of Enrollment(Participants) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Canada | 68 | 72 | 140 |
| Mexico | 379 | 355 | 734 |
| United States | 2651 | 2665 | 5316 |
| Height(cm) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Mean | 172.9 ± 9.54 | 173.0 ± 9.77 | 173.0 ± 9.65 |
| Weight(kg) | Febuxostat | Allopurinol | Total |
|---|---|---|---|
| Mean | 100.5 ± 22.47 | 100.3 ± 22.89 | 100.4 ± 22.68 |
10 further baseline measures are reported on the registry.
Showing the first 100 of 203 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2010 to primary completion in May 2017, 84 months.
Results were first posted in Jun 2018, 1 year after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 84 months is above that.
Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat